DK3017827T3 - Pneumokok-polysaccharidkonjugat-vaccine - Google Patents

Pneumokok-polysaccharidkonjugat-vaccine Download PDF

Info

Publication number
DK3017827T3
DK3017827T3 DK15195398.1T DK15195398T DK3017827T3 DK 3017827 T3 DK3017827 T3 DK 3017827T3 DK 15195398 T DK15195398 T DK 15195398T DK 3017827 T3 DK3017827 T3 DK 3017827T3
Authority
DK
Denmark
Prior art keywords
saccharide
protein
immunogenic composition
paragraph
vaccine
Prior art date
Application number
DK15195398.1T
Other languages
English (en)
Inventor
Ralph Leon Biemans
Nathalie Marie-Josephe Garcon
Philippe Vincent Hermand
Jan Poolman
Mechelen Marcelle Paulette Van
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39133667&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3017827(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526232A external-priority patent/GB0526232D0/en
Priority claimed from GB0607087A external-priority patent/GB0607087D0/en
Priority claimed from GBGB0607088.2A external-priority patent/GB0607088D0/en
Priority claimed from GB0609902A external-priority patent/GB0609902D0/en
Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en
Priority claimed from GB0620337A external-priority patent/GB0620337D0/en
Priority claimed from GB0620816A external-priority patent/GB0620816D0/en
Priority claimed from GB0620815A external-priority patent/GB0620815D0/en
Priority claimed from PCT/GB2006/004634 external-priority patent/WO2007068907A2/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of DK3017827T3 publication Critical patent/DK3017827T3/da
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

1. Immunogen sammensætning omfattende S. pneumoniae-kapselsaccharidkonjugater fra serotyper 19A og 19F, hvor 19A er konjugeret til et første bakterielt toxoid, som er pneumolysin, difteritoxoid eller CRM197, og 19F er konjugeret til et andet bakterielt toxoid, der er difteritoxoid eller CRM197, og yderligere omfattende kon-jugater af S. pneamon/'ae-kapselsaccharider 4, 6B, 9V, 14, 18C, 23F, 1, 5 og 7F, hvor gennemsnitsstørrelsen af 19A-saccharidet er mellem 110 og 700 kDa.
2. Immunogen sammensætning ifølge krav 1, der yderligere omfatter et konjugat af S. pneamon/'ae-kapselsaccharid 22F.
3. Immunogen sammensætning ifølge et hvilket som helst af de foregående krav, hvor gennemsnitsstørrelsen af 19A-saccharidet er mellem 110-300, 120-200, 130-180 eller 140-160 kDa.
4. Immunogen sammensætning ifølge et hvilket som helst af de foregående krav, hvor 19A-saccharidet er blevet dimensioneret med en faktor på ikke mere end x5.
5. Immunogen sammensætning ifølge et hvilket som helst af de foregående krav, hvor 19A-saccharidet er blevet dimensioneret ved mikrofluidisering.
6. Immunogen sammensætning ifølge et hvilket som helst af de foregående krav, hvor gennemsnitsstørrelsen af sacchariderne er over 50 kDa.
7. Immunogen sammensætning ifølge krav 6, som omfatter serotype 1 med en gennemsnitlig saccharidstørrelse på mellem 300 og 400 kDa.
8. Immunogen sammensætning ifølge krav 6 og 7, som omfatter serotype 5 med en gennemsnitlig saccharidstørrelse på mellem 350 og 450 kDa.
9. Immunogen sammensætning ifølge et hvilket som helst af kravene 6 til 8, som omfatter serotype 7F med en gennemsnitlig saccharidstørrelse på mellem 200 og 300 kDa.
10. Vaccine omfattende den immunogene sammensætning ifølge et hvilket som helst af kravene 1 til 9 og et farmaceutisk acceptabelt excipiens.
11. Fremgangsmåde til fremstilling af vaccinen ifølge krav 10, omfattende trinnet at blande den immunogene sammensætning ifølge et hvilket som helst af kravene 1 til 9 med en farmaceutisk acceptabel excipiens.
12. Immunogen sammensætning ifølge krav 1-9 eller vaccinen ifølge krav 10 til anvendelse i behandling eller forebyggelse af sygdom forårsaget af Streptococcus pneumo-n/'ae-infektion.
13. Immunogen sammensætning ifølge krav 1-9 eller vaccinen ifølge krav 10 til anvendelse i behandling eller forebyggelse af sygdom forårsaget af Streptococcus pneumo-n/'ae-infektion ifølge krav 12, hvor sygdommen er enten eller både lungebetændelse og invasiv pneumokok-sygdom (IPS) hos ældre mennesker, eksacerbationer af kronisk ob-struktiv lungesygdom (KOL) hos ældre mennesker, otitis media hos spædbørn, meningitis og/eller bakteriæmi hos spædbørn, eller lungebetændelse og/eller konjunktivitis hos spædbørn.
DK15195398.1T 2005-12-22 2006-12-20 Pneumokok-polysaccharidkonjugat-vaccine DK3017827T3 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0526232A GB0526232D0 (en) 2005-12-22 2005-12-22 Vaccine
GB0607087A GB0607087D0 (en) 2006-04-07 2006-04-07 Vaccine
GBGB0607088.2A GB0607088D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
PCT/GB2006/004634 WO2007068907A2 (en) 2005-12-13 2006-12-12 Vaccine compositions comprising a saponin adjuvant
EP06830744.6A EP1973564B1 (en) 2005-12-22 2006-12-20 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates

Publications (1)

Publication Number Publication Date
DK3017827T3 true DK3017827T3 (da) 2019-02-18

Family

ID=39133667

Family Applications (5)

Application Number Title Priority Date Filing Date
DK10192663.2T DK2384765T3 (da) 2005-12-22 2006-12-20 Vaccine mod Streptococcus pneumoniae.
DK15195398.1T DK3017827T3 (da) 2005-12-22 2006-12-20 Pneumokok-polysaccharidkonjugat-vaccine
DK06841492.9T DK1968631T3 (da) 2005-12-22 2006-12-20 Vaccine
DK06830744.6T DK1973564T3 (da) 2005-12-22 2006-12-20 Vaccine omfattende streptococcus pneumoniae-kapselpolysaccharidkonjugat
DK06830743.8T DK1962899T3 (da) 2005-12-22 2006-12-20 Pneumococcus-polysaccharid-konjugat-vaccine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10192663.2T DK2384765T3 (da) 2005-12-22 2006-12-20 Vaccine mod Streptococcus pneumoniae.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK06841492.9T DK1968631T3 (da) 2005-12-22 2006-12-20 Vaccine
DK06830744.6T DK1973564T3 (da) 2005-12-22 2006-12-20 Vaccine omfattende streptococcus pneumoniae-kapselpolysaccharidkonjugat
DK06830743.8T DK1962899T3 (da) 2005-12-22 2006-12-20 Pneumococcus-polysaccharid-konjugat-vaccine

Country Status (37)

Country Link
US (10) US20090010959A1 (da)
EP (10) EP1962899B1 (da)
JP (7) JP5792920B2 (da)
KR (5) KR101441368B1 (da)
CN (6) CN101378778B (da)
AR (3) AR058707A1 (da)
AT (1) ATE520415T1 (da)
AU (4) AU2006327036B2 (da)
BR (3) BRPI0620163B8 (da)
CA (5) CA2633772C (da)
CL (1) CL2013002106A1 (da)
CR (2) CR10119A (da)
CY (5) CY1112677T1 (da)
DK (5) DK2384765T3 (da)
EA (3) EA014107B1 (da)
ES (4) ES2707499T3 (da)
HK (1) HK1120230A1 (da)
HR (4) HRP20110685T1 (da)
HU (3) HUE041979T2 (da)
IL (5) IL191913A (da)
JO (1) JO2813B1 (da)
LT (3) LT3017827T (da)
MA (3) MA30062B1 (da)
MX (2) MX2008008140A (da)
MY (4) MY160199A (da)
NO (4) NO345368B1 (da)
NZ (4) NZ569168A (da)
PE (2) PE20071305A1 (da)
PH (1) PH12014502544A1 (da)
PL (5) PL1973564T3 (da)
PT (5) PT1973564T (da)
SG (1) SG168517A1 (da)
SI (5) SI1962899T1 (da)
TR (1) TR201900418T4 (da)
TW (4) TWI487534B (da)
UA (2) UA96934C2 (da)
WO (3) WO2007071710A2 (da)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534402T1 (de) * 2000-06-29 2011-12-15 Smithkline Beecham Biolog Multivalente impfstoffzusammensetzung
DE60117164T2 (de) 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
PL1896061T3 (pl) * 2005-06-27 2020-02-28 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
CA2633772C (en) 2005-12-22 2015-09-15 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
BRPI0715975A2 (pt) * 2006-08-17 2014-03-18 Uab Res Foudation Fragmento imunogênico de pcpa, composição,recipiente, métodos de gerar anticorpos específicos para pcpa em um indivíduo, de prevenir ou reduzir portador nasal pneumocócico em um indivíduo, e de reduzir o risco de uma infecção pneumocócica em um indivíduo, e, polipeptídeo isolado
US8398985B2 (en) * 2007-04-23 2013-03-19 Serum Institute Of India Ltd. Antigenic polysaccharides and process for their preparation
WO2008135514A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
MX340096B (es) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Formulaciones de vacuna meningococica.
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
SI2271360T1 (sl) * 2008-04-16 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo
AU2009237648A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
EP2293815A4 (en) * 2008-05-22 2013-04-03 Childrens Medical Center SYNERGISTIC IMMUNOGENIC CONJUGATE FUSION-POLYSACCHARIDE PROTEIN
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
CN102300585A (zh) 2008-12-17 2011-12-28 诺华有限公司 包含血红蛋白受体的脑膜炎球菌疫苗
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
CN102438649A (zh) 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
WO2010109325A2 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
ES2552153T3 (es) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Vacuna neumocócica y usos de la misma
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
KR20110068831A (ko) * 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
AU2012222883A1 (en) * 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
MX339058B (es) * 2011-05-17 2016-05-09 Glaxosmithkline Biolog Sa Vacuna contra streptococcus pneumoniae.
ES2855474T3 (es) 2011-10-06 2021-09-23 Immunovaccine Technologies Inc Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
US9198977B2 (en) * 2012-01-30 2015-12-01 Serum Institute Of India Ltd. Immunogenic composition
CA2861946A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
PT2811981T (pt) * 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
EP2822586A1 (en) * 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2510281C2 (ru) * 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
HUE041381T2 (hu) * 2012-08-16 2019-05-28 Pfizer Glikokonjugációs eljárások és kompozíciók
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
CN109289045A (zh) * 2012-09-19 2019-02-01 国立大学法人大阪大学 含有肺炎球菌表面蛋白a的肺炎球菌疫苗
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2934574A1 (en) 2012-12-18 2015-10-28 GlaxoSmithKline Biologicals SA Conjugates for protecting against diphtheria and/or tetanus
PL2935299T3 (pl) * 2012-12-20 2020-05-18 Pfizer Inc. Sposób glikokoniugacji
RU2544168C1 (ru) * 2014-01-17 2015-03-10 Андрей Дмитриевич Протасов Способ формирования иммунологической памяти к антигенам streptococcus pneumoniae у пациентов с хронической обструктивной болезнью легких
CN106413747A (zh) * 2014-01-21 2017-02-15 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
JP6335326B2 (ja) * 2014-01-21 2018-05-30 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
CN103936842B (zh) * 2014-04-30 2016-03-23 重庆医科大学 肺炎链球菌溶血素突变体及其作为粘膜免疫佐剂的应用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10280409B2 (en) * 2014-11-20 2019-05-07 Biological E Limited Codon optimized polynucleotide for high level expression of CRM197
CA2980616A1 (en) * 2015-03-26 2016-09-29 Gpn Vaccines Pty Ltd Streptococcal vaccine
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
RU2600838C1 (ru) * 2015-06-08 2016-10-27 Андрей Дмитриевич Протасов Способ усиления активности факторов неспецифической защиты у пациентов с хронической обструктивной болезнью легких
WO2016199003A1 (en) * 2015-06-08 2016-12-15 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
KR20160146240A (ko) 2015-06-12 2016-12-21 전관구 염기성 계면활성제를 이용한 산화은나노 및 은나노 제조 방법
CA2989230A1 (en) * 2015-06-23 2016-12-29 Biological E Limited Multivalent pneumococcal conjugate vaccine
TWI684460B (zh) * 2015-07-21 2020-02-11 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
AR109290A1 (es) 2016-08-05 2018-11-14 Sk Chemicals Co Ltd Composición conjugada neumocócica multivalente de polisacárido y proteína
MX2019001342A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de proteina-polisacarido de neumococo multivalente.
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
CA3038155A1 (en) * 2016-09-27 2018-04-05 Immunovaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
MX2019003593A (es) 2016-09-30 2019-06-10 Biological E Ltd Composiciones de vacuna neumococica multivalente que comprenden conjugados de polisacaridos y proteinas.
EP3530285B1 (en) * 2016-10-20 2023-08-09 KM Biologics Co., Ltd. METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT
KR102083973B1 (ko) * 2016-10-28 2020-04-23 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
WO2018124959A2 (en) 2016-12-28 2018-07-05 Henriques Normark Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP7186166B2 (ja) 2016-12-30 2022-12-08 バックスサイト・インコーポレイテッド 非天然アミノ酸とのポリペプチド抗原接合体
RU2762723C2 (ru) * 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
KR102650073B1 (ko) * 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
WO2019050818A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107929728A (zh) * 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 一种肺炎球菌蛋白疫苗及其制备方法
AU2018280272C1 (en) 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
MX2020002556A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
CA3084436A1 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3749358A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. MULTIVALENT POLYSACCHARIDE-PNEUMOCOCCAL PROTEIN CONJUGATE COMPOSITION
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
AU2019256218A1 (en) 2018-04-18 2020-12-03 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN112074294A (zh) * 2018-04-30 2020-12-11 默沙东公司 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
CA3105361A1 (en) * 2018-07-04 2020-01-09 Vaxcyte, Inc. Improvements in immunogenic conjugates
CA3111459A1 (en) * 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
CN113194987A (zh) * 2018-10-12 2021-07-30 生物E有限公司 多价肺炎球菌多糖-蛋白缀合的疫苗
CA3123414A1 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7441301B2 (ja) * 2019-07-18 2024-02-29 セルトリオン， インク． 球菌多糖類－タンパク質接合体を含む免疫原性組成物
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
BR112022002467A2 (pt) 2019-09-18 2022-07-19 Alcon Inc Insertos oculares de hidrogel suave embalados a úmido
WO2021146681A1 (en) * 2020-01-17 2021-07-22 Inventprise, Llc Multivalent streptococcus vaccines
KR20210117663A (ko) 2020-03-20 2021-09-29 주식회사 보고 수직형 침지식 dpf 세척장치
CN116121106A (zh) * 2021-07-08 2023-05-16 成都生物制品研究所有限责任公司 肺炎链球菌无动物源冻干保护剂
KR20240055283A (ko) 2022-10-20 2024-04-29 우남철 Ｄｐｆ용 순환펌프 연결구

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
DE69226167T2 (de) 1991-02-15 1998-11-12 The Uab Research Foundation, Birmingham, Alabama Strukturgen von pneumokokken-protein
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ATE178907T1 (de) 1992-05-06 1999-04-15 Harvard College Rezeptorbindende region des diphtherietoxius
ATE188508T1 (de) 1992-06-18 2000-01-15 Harvard College Impfstoffe gegen diphtherietoxin
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
SI0729473T1 (en) 1993-11-17 2001-02-28 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
AU732520B2 (en) 1996-05-01 2001-04-26 Rockefeller University, The Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AU3399197A (en) 1996-06-18 1998-01-07 Alza Corporation Device for enhancing transdermal agent delivery or sampling
EP0956289A4 (en) 1996-08-16 2004-10-13 Smithkline Beecham Corp NOVEL PROKARYOTA POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
CA2269636A1 (en) 1996-11-12 1998-05-22 The Regents Of The University Of Minnesota C3 binding protein of streptococcus pneumoniae
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA2271167C (en) 1996-12-20 2007-01-09 Alza Corporation Device and method for enhancing transdermal agent flux
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
NZ501911A (en) 1997-06-03 2001-12-21 Connaught Lab Lactoferrin receptor genes (Lbp1, Lbp2 and/or ORF3) of Moraxella to be used in diagnosis or treatment of Moraxella related diseases such conjunctivitis, sinusitis or urogenital infections
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2305016A1 (en) 1997-09-24 1999-04-01 Regents Of The University Of Minnesota Human complement c3-degrading proteinase from streptococcus pneumoniae
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
EP1035867A1 (en) 1997-12-02 2000-09-20 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU3479699A (en) 1998-04-07 1999-10-25 St. Jude Children's Research Hospital A polypeptide comprising the amino acid of an n-terminal choline binding proteina truncate, vaccine derived therefrom and uses thereof
HUP0102617A3 (en) 1998-04-07 2006-04-28 Medimmune Inc Gaithersburg Derivatives of pneumococcal choline binding proteins for vaccines
AU770378B2 (en) 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
BR9911329A (pt) 1998-06-30 2001-10-16 Om Pharma Novos pseudodipeptìdeos de acila, processo de preparação e composições farmacêuticas contendo os mesmos
AU771330B2 (en) 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
AU6060899A (en) 1998-09-24 2000-04-10 American Cyanamid Company Human complement c3-degrading polypeptide from (streptococcus pneumoniae)
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
GB2359228A (en) 1998-11-17 2001-08-15 Schlumberger Technology Corp Transmitting information over a communication link
AU2027400A (en) 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
AP2001002199A0 (en) 1998-12-23 2001-09-30 Shire Biochem Inc Novel streptococcus antigens
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
TWI281403B (en) * 1999-03-19 2007-05-21 Smithkline Beecham Biolog Vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2000076540A2 (en) 1999-06-10 2000-12-21 Med Immune, Inc. Streptococcus pneumoniae proteins and vaccines
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
ATE534402T1 (de) * 2000-06-29 2011-12-15 Smithkline Beecham Biolog Multivalente impfstoffzusammensetzung
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ATE321063T1 (de) 2000-08-04 2006-04-15 Corixa Corp Neue immunoeffectorverbindungen
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
FR2827199B1 (fr) 2001-07-10 2004-07-09 Centre Nat Rech Scient Procede et machine de fabrication ex situ de reseaux de biopuces basse et moyennes integration
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
DK1482795T3 (da) 2002-02-04 2010-02-01 Corixa Corp Nye immuneffektor-forbindelser
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
AU2003250204B8 (en) 2002-08-02 2008-07-10 Glaxosmithkline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
JP3754420B2 (ja) 2003-02-04 2006-03-15 三洋電機株式会社 二次電池用電極板及びその製造方法並びにこの電極板を用いた二次電池
NZ541969A (en) 2003-03-13 2008-01-31 Glaxosmithkline Biolog Sa Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2005000347A1 (en) 2003-06-23 2005-01-06 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
AU2005239963B2 (en) 2004-05-11 2011-01-06 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Vws Neisseria meningitidis IgtB LOS as adjuvant
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PL1896061T3 (pl) 2005-06-27 2020-02-28 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
US8007807B2 (en) * 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
US20090035326A1 (en) 2005-11-01 2009-02-05 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2633772C (en) * 2005-12-22 2015-09-15 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007243268B2 (en) 2006-04-26 2013-06-13 Micell Technologies, Inc. Coatings containing multiple drugs
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
CA2743708C (en) 2008-12-18 2018-01-09 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide

Also Published As

Publication number Publication date
UA96583C2 (uk) 2011-11-25
HUE041979T2 (hu) 2019-06-28
JP5579387B2 (ja) 2014-08-27
MY150719A (en) 2014-02-28
TR201900418T4 (tr) 2019-02-21
NO20190104A1 (no) 2008-09-18
JP5461838B2 (ja) 2014-04-02
JP2009520759A (ja) 2009-05-28
PL1962899T3 (pl) 2011-12-30
CN101378779B (zh) 2015-09-02
SI1968631T1 (sl) 2015-07-31
AU2006327036A1 (en) 2007-06-28
EP3470080A1 (en) 2019-04-17
TWI465248B (zh) 2014-12-21
CA2808919C (en) 2016-04-19
US11400147B2 (en) 2022-08-02
AR058706A1 (es) 2008-02-20
BRPI0620460A2 (pt) 2011-11-16
JP2009520761A (ja) 2009-05-28
PH12014502544A1 (en) 2015-12-14
EA014107B1 (ru) 2010-10-29
BRPI0620193B1 (pt) 2019-12-31
CA2634885A1 (en) 2007-06-28
AU2010241281A1 (en) 2010-11-25
NO20082647L (no) 2008-09-18
JP5749689B2 (ja) 2015-07-15
CA2634887A1 (en) 2007-06-28
ES2707499T3 (es) 2019-04-03
US20220354941A1 (en) 2022-11-10
SI3017827T1 (sl) 2019-01-31
EA014165B1 (ru) 2010-10-29
PE20071305A1 (es) 2007-12-14
BRPI0620460B1 (pt) 2019-08-13
IL219641A (en) 2017-10-31
JP5615323B2 (ja) 2014-10-29
BRPI0620193A2 (pt) 2011-11-01
EP3020411A1 (en) 2016-05-18
DK1968631T3 (da) 2015-06-15
AU2010241281B2 (en) 2012-12-06
EP1962899B1 (en) 2011-08-17
NO20082646L (no) 2008-09-16
EA200801344A1 (ru) 2008-12-30
WO2007071710A2 (en) 2007-06-28
JO2813B1 (en) 2014-09-15
MA30066B1 (fr) 2008-12-01
UA96934C2 (uk) 2011-12-26
EP1968631B1 (en) 2015-04-08
US20160243219A1 (en) 2016-08-25
CY1116407T1 (el) 2017-02-08
ATE520415T1 (de) 2011-09-15
BRPI0620193B8 (pt) 2021-05-25
KR20130103831A (ko) 2013-09-24
JP2012229228A (ja) 2012-11-22
US9884113B2 (en) 2018-02-06
CL2013002106A1 (es) 2014-03-07
IL192084A (en) 2013-11-28
PT3017827T (pt) 2019-01-28
BRPI0620163A2 (pt) 2011-11-01
DK2384765T3 (da) 2017-01-09
KR20140036327A (ko) 2014-03-25
CA2816182C (en) 2018-02-20
DK1962899T3 (da) 2011-10-31
AU2006327041B2 (en) 2010-08-26
NO343981B1 (no) 2019-08-05
CA2633772C (en) 2015-09-15
MY148141A (en) 2013-03-15
AU2006327041A1 (en) 2007-06-28
EP2382986A2 (en) 2011-11-02
HRP20190037T1 (hr) 2019-02-22
PE20071058A1 (es) 2007-11-27
BRPI0620163B1 (pt) 2019-08-13
LT1973564T (lt) 2016-12-27
TWI415622B (zh) 2013-11-21
JP2012211165A (ja) 2012-11-01
HRP20161682T1 (hr) 2017-01-27
CA2634887C (en) 2016-01-19
WO2007071707A2 (en) 2007-06-28
EP2382986A3 (en) 2012-08-22
IL191913A0 (en) 2009-02-11
US20090017059A1 (en) 2009-01-15
KR20080081060A (ko) 2008-09-05
AU2006327036B2 (en) 2012-11-15
AU2006327040B2 (en) 2010-08-19
AU2006327040A1 (en) 2007-06-28
CY1121376T1 (el) 2020-05-29
HRP20161681T1 (hr) 2017-01-13
IL211664A0 (en) 2011-05-31
NO20082718L (no) 2008-09-16
MY160199A (en) 2017-02-28
PT2384765T (pt) 2017-02-06
KR101365001B1 (ko) 2014-02-21
NO345368B1 (no) 2021-01-04
US20150190521A1 (en) 2015-07-09
NZ569077A (en) 2011-08-26
US10279033B2 (en) 2019-05-07
BRPI0620163B8 (pt) 2021-05-25
WO2007071711A3 (en) 2007-11-08
AR058707A1 (es) 2008-02-20
PL2384765T3 (pl) 2017-05-31
KR101441368B1 (ko) 2014-09-24
PT1968631E (pt) 2015-07-20
KR20080081063A (ko) 2008-09-05
CN101378779A (zh) 2009-03-04
EP1962899A2 (en) 2008-09-03
EP1968631A2 (en) 2008-09-17
CN103251940A (zh) 2013-08-21
CA2808919A1 (en) 2007-06-28
US20180250389A9 (en) 2018-09-06
JP5600337B2 (ja) 2014-10-01
US20180207262A1 (en) 2018-07-26
NZ569076A (en) 2011-08-26
JP5792920B2 (ja) 2015-10-14
AR058592A1 (es) 2008-02-13
WO2007071707A3 (en) 2007-09-13
KR101515078B1 (ko) 2015-04-24
CN101374548A (zh) 2009-02-25
CN101378778A (zh) 2009-03-04
KR20080081061A (ko) 2008-09-05
MY147495A (en) 2012-12-14
PT1973564T (pt) 2017-01-24
SG168517A1 (en) 2011-02-28
CA2634885C (en) 2016-04-19
NZ569168A (en) 2012-02-24
CN110179974A (zh) 2019-08-30
DK1973564T3 (da) 2017-01-16
EA200801367A1 (ru) 2008-12-30
JP2012232985A (ja) 2012-11-29
WO2007071710A3 (en) 2007-11-29
TW200738258A (en) 2007-10-16
HK1120230A1 (en) 2009-03-27
SI1962899T1 (sl) 2011-11-30
US20190262447A1 (en) 2019-08-29
EP1973564B1 (en) 2016-11-09
PL3017827T3 (pl) 2019-04-30
IL191911A (en) 2015-09-24
NO346529B1 (no) 2022-09-26
NZ596500A (en) 2013-05-31
EP2384765A2 (en) 2011-11-09
CN103585623A (zh) 2014-02-19
IL191913A (en) 2012-07-31
LT2384765T (lt) 2017-01-10
EA014649B1 (ru) 2010-12-30
HUE033081T2 (hu) 2017-11-28
SI2384765T1 (sl) 2017-03-31
CA2633772A1 (en) 2007-06-28
MX354843B (es) 2018-03-22
WO2007071710A8 (en) 2008-09-04
MA30065B1 (fr) 2008-12-01
EP2384765A3 (en) 2012-06-20
CR10119A (da) 2008-07-29
MX2008008140A (es) 2008-09-24
CY1112677T1 (el) 2016-02-10
CY1118345T1 (el) 2017-06-28
EP3130348A1 (en) 2017-02-15
KR101418240B1 (ko) 2014-07-16
US20090017072A1 (en) 2009-01-15
CN103585623B (zh) 2016-09-28
EA200801374A1 (ru) 2008-12-30
IL192084A0 (en) 2008-12-29
EP2402025A3 (en) 2012-03-07
ES2539795T3 (es) 2015-07-06
EP2402025A2 (en) 2012-01-04
PT1962899E (pt) 2011-10-19
TW201350129A (zh) 2013-12-16
LT3017827T (lt) 2019-01-10
CN110179974B (zh) 2024-01-09
EP1973564A2 (en) 2008-10-01
US20090010959A1 (en) 2009-01-08
CA2816182A1 (en) 2007-06-28
JP2014205673A (ja) 2014-10-30
US20150265702A1 (en) 2015-09-24
JP5849125B2 (ja) 2016-01-27
CY1118535T1 (el) 2017-07-12
SI1973564T1 (sl) 2017-02-28
TW200738257A (en) 2007-10-16
ES2630759T3 (es) 2017-08-23
EP3017827A1 (en) 2016-05-11
NO344187B1 (no) 2019-09-30
KR101367237B1 (ko) 2014-03-14
PL1973564T3 (pl) 2017-04-28
US9107872B2 (en) 2015-08-18
WO2007071711A2 (en) 2007-06-28
PL1968631T3 (pl) 2015-08-31
IL191911A0 (en) 2008-12-29
US10646564B2 (en) 2020-05-12
BRPI0620460B8 (pt) 2021-05-25
ES2614938T3 (es) 2017-06-02
CN101378778B (zh) 2013-02-06
EP3017827B1 (en) 2018-11-07
JP2009520760A (ja) 2009-05-28
US20100074922A1 (en) 2010-03-25
MA30062B1 (fr) 2008-12-01
EP2384765B1 (en) 2016-11-23
HUE032903T2 (hu) 2017-11-28
TWI487534B (zh) 2015-06-11
CN101374548B (zh) 2013-05-01
IL219641A0 (en) 2012-06-28
CR10122A (da) 2008-08-21
HRP20110685T1 (hr) 2011-10-31

Similar Documents

Publication Publication Date Title
US10646564B2 (en) Vaccine
DK2167121T3 (da) Vaccine omfattende Streptococcus pneumonia-kapselpolysaccharidkonjugater